



World Health
Organization

HIV/AIDS Programme

Strengthening health services to fight HIV/AIDS

WHO RECOMMENDATIONS ON THE DIAGNOSIS OF HIV INFECTION IN INFANTS AND CHILDREN

WHO Library Cataloguing-in-Publication Data

WHO recommendations on the diagnosis of HIV infection in infants and children.

1.HIV infections - diagnosis. 2.HIV infections - prevention and control. 3.Early diagnosis. 4.Children. 5.Infant. I.World Health Organization.

ISBN 978 92 4 159908 5

(NLM classification: WC 503.1)

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in ...

**WHO RECOMMENDATIONS
ON THE DIAGNOSIS OF HIV
INFECTION IN INFANTS
AND CHILDREN**

ACKNOWLEDGEMENTS

WHO wishes to acknowledge the efforts of the following for their preparations for and contributions to this guideline review process:

- Lynne Mofenson, Gayle Sherman and all the experts advising WHO;
- Preparing GRADE profiles: Martina Penazzato and Anniek de Baets;
- Technical review and calculations: Jörg Schüpbach, Artur Ramos, Martina Penazzato;
- Laboratory section: Artur Ramos, Jörg Schüpbach, Susan Fiscus;
- Medical Officer responsible: Siobhan Crowley;
- Department of HIV/AIDS staff at WHO headquarters;
- Essential Health Technologies: Gaby Vercauteren, Anita Sands and Mercedes Perez González;
- Reporting and technical editing: Bandana Malhotra, Martina Penazzato, Siobhan Crowley, Dharani Yerrakalva.
- Coordination of publication and administrative support: Victoria Anagbo, Sally Girvin, John Kirkwood

CONTENTS

	Acronyms and abbreviations.....	1
1	Executive summary	3
1.1	Recommendations.....	3
2	Introduction	6
3	Background.....	7
3.1	Objective.....	7
3.2	Audience for the guidelines	8
3.3	Preparatory work.....	8
3.4	Guideline review group	8
3.5	Process.....	8
3.6	Review date.....	9
4	Key recommendations	10
4.1	Performance requirements of commercial and non-commercial HIV assays.....	10
	Recommendation 1: HIV antibody assays	11
	Recommendation 2: HIV virological assays.....	13
4.2	Tests to diagnose HIV in infants and children below 18 months of age.....	15
	Recommendation 3.....	15
	Recommendation 4.....	15
	Recommendation 5.....	18
	Recommendation 6.....	18
	Recommendation 7.....	21
4.3	Identifying exposure to HIV	21
	Recommendation 8.....	21
	Recommendation 9.....	22
4.4	Testing symptomatic infants and children less than 18 months of age.....	23
	Recommendation 10.....	23
4.5	Testing infants who are breastfeeding	24
	Recommendation 11	24
4.6	Tests required to diagnose HIV in children 18 months or older	24
	Recommendation 12.....	24
4.7	Performance of clinical algorithms where virological testing is not available	25
	Recommendation 13.....	25
4.8	Summary tables.....	27
5	Laboratory methods for diagnosis of HIV infection in infants and children.....	29
5.1	Laboratory quality assurance	29
5.2	Commercially versus non-commercially available tests	29
5.3	Serological testing	30
	5.3.1 Specimen collection	32
	5.3.2 Timing of serological testing in infants	32

5.3.3	Interpretation of serological test results	32
5.3.4	Rapid test devices	33
5.3.5	EIA	34
5.3.6	Western blotting.....	34
5.4	Virological testing	35
5.4.1	Assays	35
5.4.2	HIV DNA testing.....	38
5.4.3	HIV RNA testing.....	38
5.4.4	Ultrasensitive p24 antigen-based testing	39
5.4.5	Specimen collection	39
5.4.6	Use of dried blood spots (DBS).....	40
5.4.7	Interpretation of nucleic acid tests in infants	41
5.4.8	Timing of virological testing.....	42
5.4.9	Reliability of virological tests in the presence of ARV exposure	43
6	Next steps	44
6.1	Dissemination and implementation.....	44
6.2	Outstanding issues for further research	44
6.3	New products or technologies required.....	45
6.4	Technical assistance, tools and advocacy required	45
	References	46

Annexes 1-6 can be accessed at <http://www.who.int/hiv/topics/paediatric/en/>

ACRONYMS AND ABBREVIATIONS

Ab	antibody	HIV	human immunodeficiency virus
Ag	antigen	HR	hazard ratio
ANC	antenatal care	IATT	Inter-Agency Task Team
ARR	absolute risk reduction: the difference in the event rate between the control group (CER) and treated group (EER); $ARR = CER - EER$	Ig	immunoglobulin
ART	antiretroviral therapy	IMAI	Integrated Management of Adolescent and Adult Illness
ARV	antiretroviral	IMCI	Integrated Management of Childhood Illness
AZT	zidovudine	infant	child less than 12 months of age
b-DNA	branched DNA (assay)	LR	likelihood ratio: the likelihood that a given test result would be expected in a patient with the target disorder compared with the likelihood that that same result would be expected in a patient without the target disorder. For a positive test result $LR+ = \text{sensitivity}/(1 - \text{specificity})$ and for a negative test result $LR- = (1 - \text{sensitivity})/\text{specificity}$.
CDC	Centers for Disease Control and Prevention	MTCT	mother-to-child transmission (of HIV)
CER	control group event rate	NAT	nucleic acid test
CHER	children with HIV early antiretroviral therapy	NASBA	nucleic acid sequence-based amplification
CI	confidence interval: the range around a study's result within which the true value would be expected to lie	NPV	negative predictive value: the proportion of people with a negative test who are free of the disease under study
CRF	circulating recombinant forms	NNT	number needed to treat: the number of patients who need to be treated to prevent one outcome
DBS	dried blood spot	OR	odds ratio
DPS	dried plasma spot	p24 Ag	p24 antigen (assay)
EER	evaluation event rate	PBMC	peripheral blood mononuclear cell
EIA	enzyme immunoassay		
ELISA	enzyme-linked immunosorbent assay		
EQAS	external quality assessment scheme		
FN	false negative		
FP	false positive		
GRADE	grading of recommendations assessment, development and evaluation		

PCR	polymerase chain reaction	Sn	sensitivity: the probability of having a positive test result when the disease is truly present
PEP	post-exposure prophylaxis	SOP	standard operating procedure
PHCW	primary health-care worker	STARD	standards for the reporting of diagnostic accuracy studies
PICO	population, intervention, comparator and outcome	TMA	transcription-mediated amplification
PICOT	population targeted, intervention, comparator, outcome and time	TN	true negative
PITC	provider-initiated testing and counselling	TP	true positive
PMTCT	prevention of mother-to-child transmission (of HIV)	UNAIDS	Joint United Nations Programme on HIV/AIDS
POC	point of care	UNICEF	United Nations Children's Fund
PPV	positive predictive value: the proportion of people with a positive test who have the disease under study	Us p24 Ag	ultrasensitive p24 antigen
QA	quality assurance	WB	western blot
QADAS	quality in diagnostic and screening tests	VL	viral load
RCT	randomized controlled trial	VQA	virology quality assessment
RR	relative risk	WHO	World Health Organization
RT	reverse transcriptase	WITS	Women and infants transmission study
SdNVP	single-dose nevirapine		
Sp	specificity: the probability of having a negative test result when the disease is truly absent		

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29100

